Based in Boston, MA, STRM.BIO is a pre-clinical, VC-backed biotechnology company that is leveraging extracellular vesicles (EVs) to deliver gene therapy in a better way: simpler, safer, practical. STRM.BIO’s proprietary non-viral delivery technology addresses current bottlenecks in gene therapy, allowing for targeted delivery of a variety of payloads, with large carrying capacity and the ability to repeat dose.